Alexion Pharmaceuticals reports that the U.S. Food and Drug Administration has approved Strensiq™ (asfotase alfa) for the treatment of patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP).

Strensiq, an innovative enzyme replacement therapy, is the first therapy approved in the U.S. for the treatment of patients with HPP, a genetic, chronic, and progressive ultra-rare metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications … more

Alexion said the average annual U.S. price of Strensiq will be $285,000, with weight-based dosing and other factors taken into account … more